Unique possibilities for use of Danish Healthcare Data
Join our webinar 18 November 2020 to learn more about the new Danish Data Analytics Center that offers unique possibilities for the use of Danish health data and research capacity to support development and use of new innovative medicines.
The Danish Medicines Agency’s Data Analytics Center (DAC) will officially open 16th of November 2020. DAC will be the first Data Analytics Center of its kind in Europe, supporting regulatory decision-making as well as creating a globally unique research infrastructure to be used by industry partners.
This webinar will present the visions for DAC and the opportunities for industry collaboration. DAC will enable the Danish Medicines Agency (DKMA) to offer more precise scientific advice to the pharmaceutical companies on the development of new medicines, including medicines for people with rare diseases and small patient groups.
Webinar program
- Presentation of DKMA and DAC by Thomas Senderovitz, Director General, DKMA and Jesper Kjær, Director of Division (DAC).
- Description of the visions for DAC and the concrete services that DAC offers industry partners.
- Description of how DAC will shape the European regulatory landscape – offering new possibilities for development of personalized medicine (supporting both pre- and post-marketing research activities).
- Presentation of the research community collaborating closely with DAC – which also offers unique possibilities for industry-university collaboration on health data analysis and use of Danish health registry data. By Professor Anton Pottegaard.
- Presentation of ongoing and finalized research on “Cohort of all Danish COVID-19 patients that is continuously updated and linked to the existing Danish health and administrative registries”.
- Q&A with DKMA and DAC top management and leading pharmaco-epidemiological university researchers.
Speaker info
Thomas Senderovitz
Thomas took over as Director General of the Danish Medicines Agency on 1 April 2016. His career includes more than 20 years working intensively with medicinal products and he has held several senior positions in international biopharmaceutical companies (Ferring Pharmaceuticals, UCB Pharma, Grünenthal GmbH). Most recently, he was a member of the management team of the global contract research organisation PAREXEL engaging in clinical research for pharmaceutical and biotechnological companies. Thomas previously worked at the Clinical Pharmacological Department at Bispebjerg Hospital in Copenhagen. Thomas is a member of EMAs Management Board and Chair of the HMA Management Group. He is member of the Reference Group for Crown Prince Frederik centre for Public Leadership and member of Dataetisk Råd.
Jesper Kjær
Director of Division, Data Analytics Center (DAC). Jesper brings long experience of data handing, analyses and data visualisation having worked in the academic environment and pharmaceutical industry, and he has developed IT systems for the World Health Organization and Rigshospitalet. Jesper has also led the development of risk-based monitoring IT in Novo Nordisk and has headed activities in EU Framework Programmes, TransCelerate Biopharma and HL7.
Anton Pottegård
Professor of pharmacoepidemiology at University of Southern Denmark and ‘head of research’ at Hospital Pharmacy Funen at Odense University Hospital. His research focuses on the use of drugs in its broadest sense. Typically, He uses ´real-world’ data from Danish or international health care registries, to study and identify effects as well as side effects of medicines. Using such data, he has published more than 200 papers in various medical journals.
Moderator: Allan Skaarup Kristensen
Science & Innovation Attaché at Innovation Centre Denmark Silicon Valley / San Francisco. ICDK SV builds bridges and facilitate partnerships between Danish and U.S. companies, research institutions and public stakeholders. Allan has previously worked for the Association of the Pharmaceutical Industry, the Society of Engineers and the Ministry of Higher Education and Science. He has 25 years of experience in the field of research policy and innovation and has in-depth knowledge about strategic planning of public research programs, research funding and foresight methods.
Facts Why Denmark
Background info An exclusive webinar series on personal medicine
Invest in Denmark, which is part of The Danish Ministry of Foreign Affairs, and the Danish Association of the Pharmaceutical Industry (Lif) invite pharmaceutical companies to an exclusive 5 part webinar series on the possibilities for research and development in relation to personalized medicine. The webinar series will provide an overview of the Danish research infrastructure and an opportunity for virtual meetings with leading Danish researchers and physicians as well as key officials from public health data organizations, including biobanks, health data, clinical and technology research. Attending the series will provide a direct pathway to access the unique framework that Denmark offers for pharmaceutical companies for the research, development, and clinical use of personalized medicine. The attendance is limited exclusively to global pharmaceutical companies.
-
Episode 1: DAC – the first Data Analytics Center of its kind in Europe
How DAC will shape the European regulatory landscape – offering new possibilities for development of personalized medicine (supporting both pre- and post-marketing research activities).
-
Episode 2: Biobanks supporting Personalized Medicine
How can Danish Biobanks be utilized for research? What are the opportunities for pharmaceutical companies? What are the key accomplishments and the next milestones?
-
Episode 3: Clinical Research for Personalized Medicine
Introduction to Trial Nation, a public private organization that offers a single, national entry point for life science companies that wish to conduct clinical trials in Denmark.
-
Episode 4: Exceptional Nationwide Access to Real World Data
Danish health data registries provide unique access to real world data, based on patient data, which can highlight the value (safety and effect) of new personalized medicine. Presentations and concrete examples.
-
Episode 5: Combining the Unique Elements of the Danish Framework Conditions and Competences into one Project – a world class case study
The series will be free of charge and hosted by Invest in Denmark and the Danish Association of the Pharmaceutical Industry and provide a direct pathway to a number of leading Danish experts in their fields.
The webinar series on personalized medicine origins from a physical seminar on personalized medicine which was scheduled to take place in spring 2020. Due to the COVID-19 pandemic, the seminar was cancelled. As the situation still is critical, and the consequences of this pandemic is too difficult to assess right now, the physical seminar is turned into short online seminars - a webinar series.
Download original program from May 2020.